Medical devices, healthcare technology and the business of care
510(k) clearance · K261368

Rapid Platform (R6.7)

Ischemaview, Inc. · Decision date Sep 21, 2026

MEDTECHLEDGER EXPLANATIONK261368

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 21, 2026 for K261368, the Rapid Platform (R6.7) submitted by Ischemaview, Inc. of Golden, Colorado. The submission is a traditional 510(k) under 21 CFR 892.2050, classified as Automated Radiological Image Processing Software in the Radiology panel, with primary product code QIH and subsequent codes LLZ, POK, PZO, QAS and QFM. The public database lists a receipt date of April 27, 2026, while the FDA letter cites a device-dated date of August 18, 2026 and a received date of August 19, 2026; the discrepancy is unexplained in the available text.

The clearance covers a software platform that performs viewing, processing and analysis of DICOM-compliant CT and MRI data, coordinating modules such as CTP/MRP, CTA, ASPECTS, ICH, LVO and NCCT Stroke. The summary names iSchemaView Rapid (K233512) as primary predicate and lists earlier clearances including K121447 and K213165. SESE means clearance to market, not PMA approval. The available documents do not state performance testing results, so the evidentiary basis for the equivalence determination remains unknown.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Sep 21, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261368
Regulatory pathway
510(k) premarket notification
Product code
QIH
Decision code
SESE
Decision date
Sep 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated Radiological Image Processing Software.

Product code
QIH
FDA device class
2

FDA decision timeline

  1. K261368 received

    Application receipt date recorded by FDA.

  2. K261368 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QIH

Product / regulatory recordCompanyPathwayDecision dateSource
Clever OneK260372
Ewoosoft Co., Ltd.510(k) clearanceNov 4, 2026FDA
Peek Health, S.A.510(k) clearanceNov 4, 2026FDA
AVICENNA.AI510(k) clearanceOct 19, 2026FDA
UAB Ligence510(k) clearanceOct 7, 2026FDA
NeuroDRK262134
Deep Reasoning Ai, Inc.510(k) clearanceOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ischemaview, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Golden, CO

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records